Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

Nektar Therapeutics (NKTR) incurred a first-quarter 2025 adjusted loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, the company had reported a loss of 18 cents per share.Total revenues in the first quarter decreased 51.4% year over year to $10.5 million. The reported figure also missed the Zacks Consensus Estimate of$18 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The year-over-year revenue decrease was d ...